BEAM News and Press, Beam Therapeutics Inc. From 12/09/22

Summary Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Editas Medicine's declaration of positive safety and efficacy data from its first two patients enrolled and treated under the Ruby tr...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note: On Tuesday, Dec. 13, at 4 p.m. Eastern time, Louis Navellier, Eric Fry, and Luke Lango are gathering for a special event – the Early Warning Summit – to give you their investing game...

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe ’s 2022 Top Places to Work in the &#...

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigatio...

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech S...

Summary The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metrics. Fast facts on IDNA. 10 stocks cheaper than their peers in No...

CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an ope...

Summary ARKK bears have failed to gain decisive selling momentum against its COVID lows. Hence, our thesis of a consolidation zone since May 2022 remains intact. We gleaned that ARKK bears could lose further momentum as we could be approaching maximum Fed hawkishness. Therefore, t...

Shares of Beam Therapeutics (NASDAQ: BEAM) , a clinical-stage base-editing company, are under heavy pressure today. Specifically, the company's stock is down by a noteworthy 12% on higher-than-normal volume as of 10:36 a.m. ET Monday morning. What's causing investors to hit the ...

Beam Therapeutics ( NASDAQ: BEAM ), a biotech focused on genetic medicines, announced Monday that the company will not file an investigational new drug (IND) for base editing candidate BEAM-102 targeting sickle cell disease in 2022. The shares dropped ~5% in reaction. Th...